Life Healthcare

Summarised Group results

for the year ended **30 September 2023,**
and cash dividend declaration

Our core purpose is

Making life better

International healthcare provider

Offering an integrated healthcare model and diagnostic imaging capability

Diversified offering

With a growing share of revenue and earnings from non-acute sources

Clinical excellence, analytics and technology

Focus on our employees, clinicians, clinical excellence and using analytics and technology to positively impact patient care

Our vision

Our **vision** is to be an international healthcare provider delivering **measurable clinical quality** through a **diversified** offering and **people-centred** approach.

Our mission

We **improve** the lives of people through the **delivery** of **high-quality**, **cost-effective care**.

Highlights

REVENUE FROM CONTINUING OPERATIONS

+10.3%

NORMALISED EBITDA[1] FROM CONTINUING OPERATIONS

+4.4%

NORMALISED EARNINGS PER SHARE[2] (NEPS) FROM CONTINUING OPERATIONS

+11.4%

to 89.1 cents

TOTAL DIVIDEND

+10.0%

to 44 cents per share

SIGNIFICANT TRANSACTION ANNOUNCED

- Announced the proposed disposal of Alliance Medical Group (AMG), for an enterprise value of GBP910 million, subject to shareholder approval and other conditions precedent

SOUTHERN AFRICA (SA) HOSPITAL AND COMPLEMENTARY SERVICES PAID PATIENT DAYS (PPDS)

+9.5%

+18.2%

GROWTH IN LIFE MOLECULAR IMAGING (LMI) REVENUE

1 *Life Healthcare defines normalised EBITDA as operating profit before depreciation on property, plant and equipment, amortisation of intangible assets and non-trading-related costs and income. Normalised EBITDA is a non-IFRS measure.*

2 *Normalised earnings is a non-IFRS measure which excludes non-trading-related costs and income.*

Commentary

On 5 October 2023, the Group announced the proposed disposal of its investment in Alliance Medical Group (AMG)[3]. The proposed transaction is subject to certain conditions precedent, including a shareholder vote on 8 December 2023. The proposed transaction is expected to close during the second quarter of the 2024 financial year. As a result of the proposed transaction, AMG has been disclosed as a discontinued operation and is not included in the results of the continuing operations for the twelve months to 30 September 2023 (FY2023, or the current year) nor those of the twelve months to 30 September 2022 (FY2022, or the prior year).

Life Healthcare has delivered a strong operating performance in FY2023. Group revenue from continuing operations grew by 10.3% to R22.6 billion (FY2022: R20.5 billion). Group normalised EBITDA from continuing operations increased by 4.4% to R3.6 billion (FY2022: R3.4 billion).

OPERATIONAL REVIEWS

Summarised financials

	2023 R'm	2022 R'm	% change
Revenue from continuing operations			
Southern Africa	**21 985**	19 971	10.1
Hospitals and complementary services	**20 665**	18 615	11.0
Healthcare services	**1 320**	1 356	(2.7)
International			
Radiopharmaceutical products	**656**	555	18.2
	22 641	20 526	10.3
Normalised EBITDA[4] from continuing operations			
Southern Africa	**3 637**	3 378	7.7
Hospitals and complementary services	**3 475**	3 246	7.1
Healthcare services	**162**	132	22.7
International			
Radiopharmaceutical products	**(113)**	(35)	>(100)
Growth initiatives	**–**	(15)	
Corporate	**70**	115	(39.1)
Recoveries	**1 601**	1 389	15.3
Corporate costs	**(1 531)**	(1 274)	(20.2)
	3 594	3 443	4.4

[3] *On 5 October 2023, the Group, acting through its wholly owned indirect subsidiary in the United Kingdom (UK), Alliance Medical Group Limited (AMGL), concluded binding transaction agreements with Andromeda Bidco Limited (the purchaser), for the sale of 100% of the issued share capital of Alliance Medical AcquisitionCo Limited and its subsidiaries, which together comprise the Alliance Medical Group (herein referred to as AMG), to the purchaser (the proposed transaction). The proposed transaction excludes the Group's interests in Life Molecular Imaging Limited, Life Molecular Imaging GmbH and Life Molecular Imaging Inc. (together, LMI), which do not fall within the perimeter of the proposed transaction. The purchaser is indirectly wholly owned by iCON Infrastructure Partners VI (iCON Infrastructure VI). iCON Infrastructure VI comprises two parallel limited partnerships, iCON Infrastructure Partners VI, L.P. and iCON Infrastructure Partners VI-B, L.P. iCON Infrastructure LLP (iCON Infrastructure) is the exclusive investment adviser to iCON Infrastructure VI.*

[4] *Normalised EBITDA is defined as operating profit before depreciation on property, plant and equipment, amortisation of intangible assets and non-trading-related costs or income. Normalised EBITDA of the discontinued operation was excluded in the prior year.*

Key highlights for the year include:

- SA revenue grew 10.1% year-on-year and normalised EBITDA (after corporate costs) grew 6.6% driven by strong hospitals and complementary services paid patient day (PPD) growth of 9.5%;
- LMI revenue grew 18.2% year-on-year driven by continued demand for its pipeline of radioisotopes in ongoing clinical trials, as well as a contribution from sales of NeuraCeq®;
- NEPS from continuing operations, which excludes non-trading related items, grew by 11.4% year-on-year;
- The Group remains in a strong financial position with net debt to normalised EBITDA from continuing and discontinued operations at 2.0x; and
- The Board has declared a final cash dividend of 27.0 cents per share, 8.0% higher year-on-year, bringing the total dividend for the year to 44.0 cents per share, 10.0% higher year-on-year.

Southern Africa

In SA, the hospitals and complementary services segment comprises all the acute hospitals and complementary services which include mental health, acute rehabilitation, renal dialysis, oncology and imaging services. The healthcare services segment comprises Life Nkanyisa and Life Health Solutions.

The Group's SA operations experienced strong demand for their services in the current year driven by the Group being the preferred network provider for medical aids. This led to higher utilisation of the Group's hospitals and complementary services which PPD growth of 9.5%. Revenue for SA grew by 10.1% to R22.0 billion (FY2022: R20.0 billion). Normalised EBITDA (including corporate costs and growth initiatives) grew 6.6% to R3.7 billion (FY2022: R3.5 billion), resulting in a margin of 16.9% compared to 17.4% for FY2022. This result is reflective of inflationary pressures on salaries, the impact of loadshedding on costs, mix change in admissions, including lower revenue per PPD, and increased corporate overheads, largely due to increased IT costs and investment in product development teams.

The business secured additional network deals with the Government Employee Medical Scheme (GEMS) and Medscheme. These networks came into effect in January 2023 and position Life Healthcare as the foremost designated network services provider in the country. Patient volumes from the addition of these network deals, and a continuation of the trend in activities to return to a more normalised mix, helped to drive the strong hospitals and complementary services PPD growth of 9.5% seen during FY2023. This strong PPD growth has, however, introduced higher growth in a case mix with lower revenue per PPD. The has resulted in revenue per PPD growth, for the acute hospitals business, being flat year-on-year.

As part of our portfolio optimisation, we closed two facilities during the year: a small maternity facility in Gauteng and an acute rehabilitation facility in Bloemfontein. Excluding these closures, the growth in PPDs for FY2023 would have been 9.9% compared to FY2022.

In line with our strategy of growing the non-acute portion of our business:

- We rolled out our integrated care product for patients with chronic kidney disease in January 2023. This product is designed to improve the patient experience and clinical outcomes, while also being more cost effective for funders;
- We advanced our molecular imaging capability in SA with the acquisition of the non-clinical imaging operations of TheraMed and PET Vision, both Gauteng-based nuclear imaging businesses, which together operate three outpatient clinics, adding PET-CT and SPECT capabilities to our SA imaging business; and

- On 19 May 2023, we announced the acquisition of the assets and operations of Fresenius Medical Care's renal dialysis clinics in SA. This transaction remains subject to approval by the Competition Commission in South Africa, having already obtained the necessary approvals in Eswatini and Namibia.

In our SA business, R1.3 billion was spent on capex during the current year (FY2022: R1.3 billion). A significant proportion of this capex (R1.2 billion) was spent on maintenance capex for our existing facilities. We also deployed R175 million into various growth projects, excluding the TheraMed and PET Vision transactions detailed above (refer to note 28 of the 2023 Annual Financial Statements (AFS).

Hospitals and complementary services

Our acute hospitals delivered strong results in the current year. Admissions grew 8.1% year-on-year while PPDs grew by 10.2%, benefiting from the new network deals which commenced in January 2023. Our length of stay increased by 2.0% to 3.8 days in FY2023 versus 3.7 days in FY2022.

Medical PPDs (excluding COVID-19 PPDs) grew by 20.6% during FY2023, while surgical PPDs grew by 10.1%. COVID-19 PPDs declined by c.73% and made up c.1% of total PPDs. These mix changes bring the total medical PPDs split to 50.2% versus 49.8% for surgical PPDs, a ratio that is now very similar to 2019 levels.

The strong PPD growth translated into higher occupancies across our acute hospital facilities, with weighted average occupancy of 67.6% in the current year versus 61.1% in the prior year. Average occupancy levels during the second half of the year were 70.2%.

Acute hospital revenue grew 10.3% year-on-year after being positively impacted by the strong PPD volume growth. Due to changes in the mix of patients within our facilities, revenue per PPD for FY2023 was flat versus the prior financial year impacted by the change in the case mix and the network discounts.

Our complementary services also performed very strongly in the current year with revenue growth of 20.4% year-on-year. The complementary services business experienced PPD growth of 4.1% for FY2023, driven by a recovery in mental health PPDs of 8.4%, while acute rehabilitation PPDs declined by 3.8% following the closure of a facility in Bloemfontein. Excluding the impact of the closed facility, PPDs for complementary services would have grown by 6.8% year-on-year and PPDs for acute rehabilitation would have grown by 3.3%.

Renal dialysis treatments grew by 9.6% during FY2023, demonstrating the resilience of this service and early evidence of uptake of our integrated renal product which was launched in January 2023. This product has been well received by patients and funders and we anticipate signing up additional funders onto the product during 2024.

The Fresenius Medical Care transaction will see Life Healthcare acquire 51 renal dialysis clinics, integrate their 500 employees and continue to support their c. 2 500 patients in South Africa, Namibia and Eswatini. This transaction supplements the existing 31 renal dialysis clinics within our complementary services business and significantly enhances our countrywide renal dialysis footprint. The transaction remains subject to approval of the Competition Commission in South Africa, after having received approval in Namibia and Eswatini.

Oncology treatments grew by 15.0% during the current year. The Varian Ethos radiotherapy machine which was installed at our Life Vincent Pallotti Hospital has seen good utilisation as our team of oncologists embrace this cutting-edge technology. In addition, the completion of the new oncology ward, with an additional 12 chemotherapy stations in Q1 FY2023, at Life Vincent Pallotti Hospital positions this facility as an oncology centre of excellence.

SA imaging scan volumes grew by 92% during the current year, with both East Coast Radiology (ECR) and Eugene Marais Radiology (EMR) continuing to deliver ahead of expectations in terms of volumes and revenue. The strong volume growth is partly attributable to a full year of activity from these facilities within FY2023, whereas in FY2022 ECR was included from February 2022 onwards, while EMR was only included from August 2022 onwards. Also included in the FY2023 imaging activity volumes is a small contribution of PET-CT and SPECT scans from the TheraMed acquisition which became effective from 1 June 2023 and the PET Vision acquisition which became effective from 1 August 2023.

These transactions are complementary to the two cyclotrons we are developing under a joint venture with AXIM. Building work for these cyclotrons commenced during 2023.

Healthcare services

Revenue from our healthcare services business decreased by 2.7% to R1.3 billion (FY2022: R1.4 billion). Normalised EBITDA grew by 22.7% resulting in the normalised EBITDA margin expanding to 12.3% (versus 9.7% in FY2022).

The decline in revenue was largely due to reduced revenue and commercial contracts in Life Health Solutions during FY2022 and early FY2023. This business has been restructured during the last 12 months and this restructuring, while at an early stage, has led to some normalised EBITDA margin improvement during the second half of FY2023.

Life Nkanyisa delivered another good performance during the current year with revenues growing above inflation while the high occupancies and good cost management resulted in improved normalised EBITDA margins.

International operations

The Group's international segment only includes revenue from LMI's radiopharmaceutical products.

LMI's NeuraCeq® remains the key revenue driver for LMI and continued to generate sales from the clinical trials of disease modifying drugs (DMDs) within the Alzheimer's Disease field. The approval of Leqembi™ in the US during the current year, and subsequent approval for reimbursement of both the drug and amyloid diagnostic testing needed prior to commencing treatment, are positive for LMI.

The business generated 29.2% growth in commercial volumes and sales of NeuraCeq® in FY2023 from demand from patients undergoing diagnostic testing as part of a dementia diagnosis pathway, while growth in NeuraCeq® volumes from ongoing clinical trials slowed to 7.7%.

LMI's FY2023 revenue grew 18.2% year-on-year to R656 million (FY2022: R555 million) driven by continued demand for its pipeline of radioisotopes in ongoing clinical trials, as well as a greater contribution from commercial sales of NeuraCeq®. LMI's normalised EBITDA loss increased to R113 million, from a loss of R35 million in FY2022. This is due to increased expenditure on sales and marketing headcount and setting up manufacturing arrangements during the year. This headcount increase is required to prepare the business adequately to drive increased sales of NeuraCeq® following the approval of Leqembi™ in the US, and potential approvals in other geographies during our 2024 financial year.

Discontinued operations

AMG has been classified as a disposal group held for sale in terms of IFRS 5 and is disclosed as a discontinued operation in the Group's FY2023 results.

AMG delivered a good operational performance during the current year delivering over 1.2 million scans, 7.3% higher than scanning activity in FY2022. In the United Kingdom FY2023 scan volumes grew by 9.5% year-on-year with PET-CT volumes up 11.8%. Ireland continued to benefit from strong demand during the year, growing volumes by 13.6%, while Italy delivered flat volume growth.

AMG's revenue in FY2023 grew 10.1% to GBP418 million and normalised EBITDA grew 5.8% to GBP83 million.

With the application of IFRS 5, AMG needs to be measured at the lower of its fair value less transaction costs or its net asset value. As a result, at 30 September 2023, the carrying value of AMG was impaired by R822 million, a figure which is inclusive of transaction costs of R532 million. Additionally, transaction costs of R149 million were incurred before AMG was classified as held for sale, which does not form part of the impairment.

The Group acquired the business when the exchange was GBP1=ZAR17.78. On the effective date of the conclusion of the proposed transaction, (expected to close during the second quarter of FY2024), the Group is likely to recognise an exchange gain in the statement of profit or loss.

GROUP FINANCIAL PERFORMANCE

Group revenue from continuing operations increased by 10.3% to R22.6 billion (FY2022: R20.5 billion) consisting of a 10.1% increase in southern African revenue to R22.0 billion (FY2022: R20.0 billion), and an 18.2% increase in international revenue to R656 million (FY2022: R555 million). Normalised EBITDA from continuing operations increased by 4.4% to R3.6 billion (FY2022: R3.4 billion). A summary of the FY2023 results is presented below. This summary has been extracted from the 2023 AFS, which can be accessed on our website (www.lifehealthcare.co.za/investor-relations/results-and-reports/).

Summarised financials (from continuing operations)	2023 R'm	2022 R'm	% change
Revenue	**22 641**	20 526	10.3
Operating profit	**2 439**	2 762	(11.7)
Net finance cost*	**(537)**	(581)	7.6
Share of associate's net profit after tax	**9**	10	(10.0)
Tax expense	**(483)**	(703)	31.3
Profit after tax from continuing operations	**1 428**	1 488	(4.0)
(Loss)/profit for the year from discontinued operations	**(990)**	226	n/a
Profit after tax from continuing and discontinued operations	**438**	1 714	(74.4)
Non-controlling interest	**174**	183	(4.9)
Profit from continuing and discontinued operations attributable to ordinary equity holders	**264**	1 531	(82.8)

* *Includes net foreign exchange gain in the current year of R75 million (FY2022: loss of R138 million).*

Earnings per share (EPS), headline earnings per share (HEPS) and normalised earnings per share (NEPS)

The Group's overall earnings from continuing and discontinued operations have been impacted by higher interest costs, given the significant interest rate increases experienced in both SA and internationally, and by a number of non-trading items as detailed below:

- R971 million loss (impairment and transaction costs) relating to the proposed disposal of AMG (explained above);
- R152 million net positive impact compared to last year due to the settlement of the SARS VAT matter (as disclosed in our FY2022 and H1-2023 results);
- R34 million relating to an impairment in the UK (as disclosed in our H1-2023 results); and
- The prior year was positively impacted by the release of the LMI contingent consideration of R437 million (as disclosed in our FY2022 results).

Basic EPS from continuing and discontinued operations decreased by 82.7% to 18.3 cents (FY2022: 105.8 cents) while HEPS from continuing and discontinued operations decreased by 16.9% to 88.2 cents (FY2022: 106.1 cents).

NEPS from continuing and discontinued operations, which excludes non-trading-related items, decreased by 1.9% to 94.6 cents (FY2022: 96.4 cents). NEPS from continuing operations, which excludes the non-trading-related items from AMG, grew by 11.4% to 89.1 cents (FY2022: 80.0 cents). The presentation of normalised earnings metrics are non-IFRS measures.

A reconciliation of the movements between attributable earnings and NEPS, including the various non-trading items referred to above, is provided in the table below and in note 8 of the AFS.

Reconciliation of attributable earnings to normalised earnings (NEPS)[1]

	2023 R'm	2022 R'm	% change	2023 cps	2022 cps	% change
Weighted average number of shares at the end of the year (millions)	**1 442**	1 447	(0.3)			
Profit attributable to ordinary equity holders	**264**	1 531	(82.8)	**18.3**	105.8	(82.7)
Loss/(profit) from discontinued operations attributable to ordinary equity holders	**990**	(226)	n/a	**68.7**	(15.6)	n/a
Profit from continuing operations attributable to ordinary equity holders	**1 254**	1 305	(3.9)	**87.0**	90.2	(3.5)
Retirement benefit asset and post-employment medical aid income	**(25)**	(23)		**(1.7)**	(1.6)	
Fair value adjustments to contingent consideration	**7**	(406)		**0.5**	(28.1)	
Gain on derecognition of lease asset and liability	**(3)**	–		**(0.2)**	–	
International tax refund	**(14)**	–		**(1.0)**	–	
Loss on disposal of property, plant and equipment	**7**	2		**0.5**	0.1	
Transaction costs relating to acquisitions	**12**	1		**0.8**	0.1	
Unwinding of contingent consideration	**62**	75		**4.3**	5.2	
Fair value loss on equity investment	**4**	5		**0.3**	0.3	
Dispute on contract interpretation provision	**47**	199		**3.3**	13.8	
Deferred tax allocation between continuing and discontinued operations[2]	**(67)**	–		**(4.7)**	–	
Normalised earnings from continuing operations	**1 284**	1 158	10.9	**89.1**	80.0	11.4
Normalised earnings from discontinued operations	**80**	238		**5.5**	16.4	
Normalised earnings from continuing and discontinued operations	**1 364**	1 396	(2.3)	**94.6**	96.4	(1.9)

[1] *Non–IFRS measure.*

[2] *LMI's carried-forward losses were previously assumed to be surrendered (for nil consideration) to the other UK entities within the AMG Group, as these entities form part of the same tax relief group within the UK. Due to the proposed disposal, the Group relief allocation has been amended resulting in additional losses being carried forward in LMI. An increased deferred tax asset has therefore been recognised in LMI. This is excluded from NEPS.*

Capital expenditure

The Group invested R1.5 billion (FY2022: R1.4 billion) in capital expenditure (capex) on continuing operations in the current year, comprised of maintenance capex for the year of R1.2 billion (FY2022: R1.1 billion) and growth capex of R366 million (FY2022: R354 million).

Financial position and liquidity

The Group remains in a strong financial position with net debt to normalised EBITDA from continuing and discontinued operations (as per bank covenant definitions) as at 30 September 2023 of 2.0 times, compared to the 1.89 times reported at 30 September 2022, and remains within our covenant of 3.5 times.

Cash generated from continuing operations was R3.7 billion and represented 101.6% of normalised EBITDA from continuing operations (FY2022: 97.0%). The available undrawn bank facilities as at 30 September 2023 amounted to R4.1 billion. After the conclusion of the proposed transaction, available bank facilities are likely to decline to R2.7 billion.

Cash dividend

The Board approved a final gross cash dividend of 27.0 cents per share. The dividend has been declared from income reserves and is subject to South African dividend withholding tax of 20%, which will be applicable to all shareholders not exempt therefrom, after deduction of which the net cash dividend is 21.60000 cents per share. This dividend declaration brings the total dividend declared for FY2023 to 44.0 cents per share (FY2022: 40.0 cents per share).

The Company's total number of issued ordinary shares is 1 467 349 162 as at 16 November 2023. The Company's income tax reference number is 9387/307/15/1.

In compliance with the requirements of the JSE, the following salient dates are applicable:

Last date to trade cum dividend	Monday, 11 December 2023
Shares trade ex the dividend	Tuesday, 12 December 2023
Record date	Thursday, 14 December 2023
Payment date	Monday, 18 December 2023

Share certificates may not be dematerialised or rematerialised between Tuesday, 12 December 2023 and Thursday, 14 December 2023, both days inclusive.

2024 Outlook

The Group plans to conclude the disposal of AMG and distribute the surplus net proceeds to shareholders. The amount anticipated for distribution to shareholders is GBP360 million. For the 12 months to 30 September 2024 (FY2024), the Group expects continued activity growth in its southern African operations driven by growth in admissions from network deals and doctors recruited.

The expected southern African PPD growth is c.3%. Changes in case mix, impact of discounted network lives, inflationary pressures on operational costs are likely to result in normalised EBITDA margins remaining flat in the southern Africa business in FY2024.

For LMI, we expect commercial sale volumes of NeuraCeq® to grow strongly in FY2024, driven by patients undergoing diagnostic PET-CT scans prior to potentially starting DMD treatment.

In FY2024 we plan to spend c.R2.1 billion on capital expenditure in SA, including R350 million on the purchase of a hospital property which is currently leased property. We also plan to spend c.R200 million on capex for LMI, largely earmarked for investment into LMI's product pipeline development.

Thanks

The Company's ability to effectively respond to operational challenges, while continuing to provide quality care to its patients, is largely due to the resilience, dedication and unwavering support of its employees, doctors and other healthcare professionals. Life Healthcare would like to thank them for their tireless work and for the care they deliver.

The Group would also like to thank AMG's employees who have not only continued to deliver excellent services for AMG's many clients across UK and Europe, but also spent considerable time and effort working with the Group and its advisors on the proposed disposal of AMG.

Audit opinion

The Company has issued its audited annual financial statements for the year ended 30 September 2023. Deloitte & Touche, the Group's independent auditor, has audited the consolidated and separate annual financial statements and has expressed an unmodified audit opinion thereon.

The financial information contained in this announcement is extracted from these audited results, however, the announcement itself is not audited.

Investor presentation

Shareholders and noteholders are advised that the investor presentation for the 12 months ended 30 September 2023 has been published on Life Healthcare's website (www.lifehealthcare.co.za/investor-relations/results-and-reports/).

Approved by the board of directors on 15 November 2023 and signed on its behalf:

Dr Victor Litlhakanyane	**Mr Peter Wharton-Hood**
Chairman	**Group Chief Executive**

Administration

Executive directors

Mr PG Wharton-Hood (Group Chief Executive), Mr PP van der Westhuizen (Group Chief Financial Officer)

Non-executive directors

Dr VL Litlhakanyane (Chairman), Dr JE Bolger, Mr PJ Golesworthy, Ms CM Henry, Mr LE Holmqvist, Prof ME Jacobs, Mr TP Moeketsi, Ms AM Mothupi, Mr JK Netshitenzhe, Adv M Sello, Mr GC Solomon and Mr F Tonelli

Company Secretary

Ms J Ranchhod

Registered Office

Building 2, Oxford Parks, 203 Oxford Road (cnr Eastwood and Oxford Roads), Dunkeld, 2196
Private Bag X13, Northlands, 2116

Equity and Debt Sponsor

Rand Merchant Bank, a division of FirstRand Bank Limited

16 November 2023

NOTE REGARDING FORWARD-LOOKING STATEMENTS

Any forward-looking statements or projections made by the Company, including those made in this announcement, are subject to risk and uncertainties that may cause actual results to differ materially from those projected, are the responsibility of the directors and have not been reviewed or reported on by the Group's external auditors.

LIFE HEALTHCARE GROUP HOLDINGS LIMITED

Registration number: 2003/002733/06
Income tax number: 9387/307/15/1
ISIN: ZAE000145892
JSE and A2X share code: LHC
(Life Healthcare, the Group, or the Company)

LIFE HEALTHCARE FUNDING LIMITED

(Incorporated in the Republic of South Africa with limited liability)
(Registration number 2016/273566/06)
Bond company code: LHFI
(Life Healthcare Funding)

Bastion

Life Healthcare

Head Office
Building 2
Oxford Parks
203 Oxford Road
Cnr Eastwood and Oxford Roads
Dunkeld
2196

www.lifehealthcare.co.za